Abiopharma

Silence Therapeutics - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Cybin - Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New Form 8-K - Nuvation Bio Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174954 Size: 319 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - PRECISION BIOSCIENCES INC Filed: 2025-08-07 AccNo: 0001628280-25-038592 Size: 237 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nuvation Bio Inc. - Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates